Filtered By:
Specialty: Drugs & Pharmacology
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 271 results found since Jan 2013.

Do CHA2DS2VASc and HAS‐BLED scores influence ‘real‐world’ anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre
ConclusionsAntithrombotic management in AF is well implemented in Polish conditions, but we show the lack of pattern concerning who is being treated with OAC and ASA when it comes to the risk of stroke and bleeding. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - September 30, 2015 Category: Drugs & Pharmacology Authors: Paulina Lopatowska, Anna Tomaszuk‐Kazberuk, Elzbieta Mlodawska, Hanna Bachorzewska‐Gajewska, Jolanta Malyszko, Slawomir Dobrzycki, Wlodzimierz J. Musial Tags: Original Report Source Type: research

Exposure–response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation
ConclusionsThe effects on thrombin generation and fibrin D‐dimer levels correlated with the plasma concentration of its active form and provided comparable effects to well‐controlled VKA therapy at an exposure at least corresponding to the 300 mg once daily dose of AZD0837.
Source: British Journal of Clinical Pharmacology - September 22, 2015 Category: Drugs & Pharmacology Authors: Gregory Y. H. Lip, Lars H. Rasmussen, S. Bertil Olsson, Eva Jensen, Bengt Hamrén, Ulf G. Eriksson, Karin Wåhlander Tags: Pharmacokinetics Source Type: research

Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities
Abstract The presence of atrial fibrillation (AF), the most common sustained cardiac arrhythmia, significantly increases the risk for stroke. Current guidelines recommend that the vitamin K antagonist warfarin or direct oral anticoagulants (DOACs), such as the approved direct thrombin inhibitor dabigatran and the approved direct factor Xa inhibitors apixaban, rivaroxaban, and edoxaban, should be used for thromboprophylaxis in patients with nonvalvular AF at risk for stroke or systemic embolic events (SEE). Warfarin, the mainstay of stroke prevention in AF, increases the risk of major bleeding. Furthermore, warfari...
Source: Drugs - September 14, 2015 Category: Drugs & Pharmacology Source Type: research

Exposure‐ response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation
ConclusionsFollowing oral therapy with AZD0837, inhibitory effects on thrombin generation and fibrin D‐dimer levels were correlated to the plasma concentration of its active form and provides comparable effects as well‐controlled VKA therapy at an exposure at least corresponding to the 300 mg qd dose AZD0837.
Source: British Journal of Clinical Pharmacology - July 14, 2015 Category: Drugs & Pharmacology Authors: Gregory Y. H. Lip, Lars H. Rasmussen, S. Bertil Olsson, Eva Jensen, Bengt Hamrén, Ulf G. Eriksson, Karin Wåhlander Tags: Pharmacokinetics Source Type: research

Warfarin and Aspirin Use for Stroke Prevention Among Patients With Atrial Fibrillation: The US National Health and Wellness Survey
This study examined VKA and ASA use and their clinical correlates, including CHADS2 stroke risk scores, among adult patients with AF in the general population. Participants included 1290 (1.72%) adults reporting diagnosis with AF (mean age, 64.9 years; 65% men) from the 2009 US National Health and Wellness Survey, an online, self-administered, nationwide, stratified random sample survey of 75,000 adults. Antithrombotic use patterns, including VKA, ASA, VKA+ASA, and non-VKA/ASA, and their correlates were examined using logistic regressions. Respondents with AF were treated with VKA (26.6%), ASA (34.5%), VKA+ASA (15.4%), or ...
Source: American Journal of Therapeutics - July 1, 2015 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice
The objective of this review is to provide the clinician with an update on the use of NOACs for NVAF, focusing on older adults and patients with renal impairment in light of recently published atrial fibrillation guidelines. Available data on using NOACs in coronary artery stenting, cardioversion, and ablation are also reviewed.
Source: Drugs - May 22, 2015 Category: Drugs & Pharmacology Source Type: research

Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?
We report a case of ischemic stroke in an 87‐year‐old woman having received intravitreal aflibercept, a new anti‐VEGF for AMD. She had been treated with ranibizumab since 2007. In 2013, ranibizumab was replaced with aflibercept, followed by a decrease in the International Normalized Ratio, complicated by a stroke a few days later. The rechallenge was positive. What is new and conclusionA potential time‐dependent interaction between aflibercept and VKA antagonist and/or a direct effect of aflibercept may have contributed to the occurrence of the ischaemic stroke. Currently available data suggest some pharmacokinetic...
Source: Journal of Clinical Pharmacy and Therapeutics - May 1, 2015 Category: Drugs & Pharmacology Authors: J. Thorel, E. Civade, J. C. Quintyn, P. Cestac, J.‐L. Montastruc, H. Bagheri Tags: Case Report Source Type: research

Diabetes mellitus and oxidative stress—a concise review
Publication date: Available online 21 March 2015 Source:Saudi Pharmaceutical Journal Author(s): Asmat Ullah , Abad Khan , Muhammad I. Khan Human body is continuously exposed to different types of agents that results in the production of reactive species called as free radicals (ROS/RNS) which by the transfer of their free unpaired electron causes the oxidation of cellular machinery. In order to encounter the deleterious effects of such species, body has got endogenous antioxidant systems or it obtain exogenous antioxidants from diet that neutralizes such species and keep the homeostasis of body. Any imbalance between the...
Source: Saudi Pharmaceutical Journal - March 22, 2015 Category: Drugs & Pharmacology Source Type: research

Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women.
Abstract Atrial fibrillation (AF), one of the most prevalent supra-ventricular arrhythmia in adults, is related to a substantial increase in the risk of thromboembolic events requiring tailored preventive strategy. In AF, antithrombotic therapy should be individualized according to a careful decision-making process, taking in account the likely concomitant presence of risk factors for stroke and bleeding. Anticoagulation management is particularly challenging in women with AF, to the extent that female sex is incorporated in commonly used stratification schemes for both thromboembolic and bleeding risk evaluation....
Source: Current Vascular Pharmacology - February 16, 2015 Category: Drugs & Pharmacology Authors: Stefania B, Valeria R, Marco P, Laura N, Patrizia F, Flavia F Tags: Curr Vasc Pharmacol Source Type: research

Recent Advances in the Development of Specific Antidotes for Target‐Specific Oral Anticoagulants
Warfarin, a vitamin K antagonist, has been the only orally available anticoagulant for > 60 years. During the past decade, the U.S. Food and Drug Administration has approved several target‐specific oral anticoagulants (TSOACs) for the prophylaxis and treatment of arterial and venous thromboembolism and stroke prevention in patients with nonvalvular atrial fibrillation. These new agents have several advantages over warfarin including more predictable pharmacokinetics and pharmacodynamics, fewer food and drug interactions, and lack of need for routine coagulation monitoring. However, unlike warfarin, currently no ant...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 3, 2015 Category: Drugs & Pharmacology Authors: Yoonsun Mo, Felix K. Yam Tags: Review of Therapeutics Source Type: research

Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin
Conclusions Amongst NOACs, apixaban may be the most economically efficient alternative to warfarin in NVAF patients who are suitable for VKA treatment and eligible for stroke prevention in Belgium.
Source: Clinical Drug Investigation - December 16, 2014 Category: Drugs & Pharmacology Source Type: research

Efficacy and toxicity of factor Xa inhibitors.
Authors: Bondarenko M, Curti C, Montana M, Rathelot P, Vanelle P Abstract Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority. New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed to overcome current therapeutic limitations. The new oral anticoagulants and parenteral otamixaban are under evaluation in clinical trials for VTE treatment, for VTE prevention in orthopedic surgery, for stroke prevention in patients with atrial fi...
Source: Journal of Pharmacy and Pharmaceutical Sciences - December 2, 2014 Category: Drugs & Pharmacology Tags: J Pharm Pharm Sci Source Type: research

Neuroprotective effect of Feronia limonia on ischemia reperfusion induced brain injury in rats
Conclusion: These observations suggest the neuroprotective and antioxidant activity of F. limonia and Vitamin E on ischemia reperfusion induced brain injury and may require further evaluation.
Source: Indian Journal of Pharmacology - November 18, 2014 Category: Drugs & Pharmacology Authors: Purushottam B RakhundeSana SaherSyed Ayaz Ali Source Type: research

Optimal Stroke Prevention in the Geriatric Patient with Atrial Fibrillation: Position Paper of an Interdisciplinary Expert Panel
Drug Res (Stuttg)DOI: 10.1055/s-0034-1389984The present position paper summarises the outcomes of an expert panel discussion held by hospital-based and office-based physicians with ample experience in the treatment of geriatric patients. The optimal approach to stroke prevention in geriatric patients with atrial fibrillation (AF) has not been adequately clarified. Despite their high risk of stroke and clear indication for anticoagulation according to established risk scores, in practice geriatric AF patients often are withheld treatment because of comorbidities and comedications, concerns about low treatment adherence or f...
Source: Drug Research - October 6, 2014 Category: Drugs & Pharmacology Authors: Bahrmann, P.Wehling, M.Ropers, D.Flohr, J.Leischker, A.Röther, J. Tags: Review Source Type: research

Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
Conclusions Apixaban is a cost-effective alternative to aspirin for patients with AF in Belgium who decline or cannot tolerate VKA treatment.
Source: Clinical Drug Investigation - September 25, 2014 Category: Drugs & Pharmacology Source Type: research